Compared with a 23-valent pneumococcal polysaccharide vaccine, a 13-valent pneumococcal conjugate vaccine was more cost-effective among adults in the United States. “Conjugate vaccines have been shown ...

Give the 13-valent pneumococcal conjugate vaccine to senior patients Give the 13-valent pneumococcal conjugate vaccine along with the 23-valent pneumococcal polysaccharide vaccine to all patients aged ...

Please provide your email address to receive an email when new articles are posted on . Although vaccines have reduced the burden of pneumococcal disease, pneumonia due to Streptococcus pneumoniae and ...

October 12, 2012 — An advisory committee to the Centers for Disease Control and Prevention has released recommendations on the use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth ...

September 7, 2010 — Guidelines have been updated for use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults, according to a report in the September 3 issue of MMWR. Morbidity and ...

(HealthDay News) — The U.S. Centers for Disease Control and Prevention have released a Category A recommendation for revised routine pneumococcal vaccination in older adults. The recommendation has ...

Credit: Getty Images. Two sequential administration groups were compared by demonstrating the antibody response curve and the reverse cumulative distribution curve analyses by serotype. This article ...

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults “Pneumococcal disease continues to pose a significant risk for adults in Europe, among adults who are 65 or ...